The placement successfully raised A$9.5 million, including A$5 million from a strategic cornerstone investor, Tian An Medicare Limited, a Hong Kong listed investment holding company, with an additional A$2 million targeted through a SPP. 

INOVIQ is a leader in exosome technology advancing next-generation diagnostics and therapeutics to transform cancer care. Its product portfolio includes commercial stage exosome isolation products, clinical stage diagnostics for ovarian and breast cancers and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours.

Funds raised from the capital raising will be used to accelerate clinical validation and LDT commercialisation of INOVIQ’s Ovarian Cancer screening test (EXO-OC test) and expedite in-vivo preclinical studies for its high value CAR-Exosome therapeutic program for solid tumours.      

The MinterEllison team was led by Sudharshan Senathirajah (Partner, M&A / Capital Markets) with support from Alexander Persano (Senior Associate, M&A / Capital Markets) and Liam Plant (Associate, M&A / Capital Markets). 

Sudharshan Senathirajah, Partner, M&A / Capital Markets at MinterEllison, said: “This capital raising marks an important milestone for INOVIQ as it accelerates innovation in cancer diagnostics and therapeutics. We’re proud to support the team in securing strategic investment that strengthens their growth trajectory.”